These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31352582)

  • 1. Re: Letter to editor: heart rate effects of antimuscarinic drugs.
    Cetinel B; Onal B; Gultekin MH
    Int Urol Nephrol; 2019 Oct; 51(10):1785-1786. PubMed ID: 31352582
    [No Abstract]   [Full Text] [Related]  

  • 2. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
    Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
    Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
    Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
    BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers.
    Poller U; Nedelka G; Radke J; Pönicke K; Brodde OE
    J Am Coll Cardiol; 1997 Jan; 29(1):187-93. PubMed ID: 8996313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
    Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimuscarinics for treatment of overactive bladder.
    Andersson KE
    Lancet Neurol; 2004 Jan; 3(1):46-53. PubMed ID: 14693111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimuscarinic actions of antihistamines on the heart.
    Liu H; Zheng Q; Farley JM
    J Biomed Sci; 2006 May; 13(3):395-401. PubMed ID: 16453179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antimuscarinic activity in human volunteers: a teaching aid in clinical pharmacology.
    Tripathi SK; Griyappanavar CR; Lal A; Biswas K; Biswas NR; Sankaranarayanan A; Sharma PL
    Indian J Physiol Pharmacol; 1995 Apr; 39(2):163-5. PubMed ID: 7649608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
    Kay GG; Abou-Donia MB; Messer WS; Murphy DG; Tsao JW; Ouslander JG
    J Am Geriatr Soc; 2005 Dec; 53(12):2195-201. PubMed ID: 16398909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Long-Term Adherence to Antimuscarinic Drugs when Treating Overactive Bladder in the Older: Subjective Reason and Objective Factors.
    Griebling TL
    J Urol; 2018 Sep; 200(3):475-476. PubMed ID: 30412940
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations.
    Andersson KE; Olshansky B
    BJU Int; 2007 Nov; 100(5):1007-14. PubMed ID: 17922785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy.
    Schwantes U; Topfmeier P
    Int J Clin Pharmacol Ther; 1999 May; 37(5):209-18. PubMed ID: 10363619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
    Olshansky B; Ebinger U; Brum J; Egermark M; Viegas A; Rekeda L
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):241-51. PubMed ID: 18832343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel imidazole derivatives with subtype-selective antimuscarinic activity (2).
    Miyachi H; Kiyota H; Segawa M
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2163-8. PubMed ID: 9873506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.
    Abrams P; Andersson KE; Buccafusco JJ; Chapple C; de Groat WC; Fryer AD; Kay G; Laties A; Nathanson NM; Pasricha PJ; Wein AJ
    Br J Pharmacol; 2006 Jul; 148(5):565-78. PubMed ID: 16751797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the Editor Re: "Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later".
    Clark K; Sheehan C; Currow DC
    J Pain Symptom Manage; 2019 Jan; 57(1):e16-e17. PubMed ID: 30367928
    [No Abstract]   [Full Text] [Related]  

  • 17. Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.
    Hartigan SM; Dmochowski RR
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):103-110. PubMed ID: 31918590
    [No Abstract]   [Full Text] [Related]  

  • 18. Which muscarinic receptor is important in the bladder?
    Yamanishi T; Chapple CR; Chess-Williams R
    World J Urol; 2001 Nov; 19(5):299-306. PubMed ID: 11760777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and demographic factors associated with antimuscarinic medication use in older hospitalized patients.
    Lowry E; Woodman RJ; Soiza RL; Mangoni AA
    Hosp Pract (1995); 2011 Feb; 39(1):30-6. PubMed ID: 21441756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?
    Khastgir J
    Expert Opin Pharmacother; 2019 May; 20(7):813-820. PubMed ID: 30724647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.